Exact Sciences' Colorectal Cancer Screening Initiative Sees Success, Undervalued Shares

Exact Sciences published a case study on its collaboration with Amalgam Rx and Privia Health to raise colorectal cancer screening rates above national benchmarks through EHR-integrated outreach and at-home noninvasive Cologuard tests. The program highlights a scalable approach to expanding access, supporting value-based care, and informing electronic quality measures. The stock closed at $103.71, with a 1-year return of 130.6% and a 3-year return of 63.2%.